Tularik clinical trials
Acquired by Amgen, Aug 13, 2004 · source ↗
The registry lists 7 studies whose lead sponsor is Tularik. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 6, 2014.
Before and after it joined Amgen
- First submitted before Tularik became part of Amgen
- 7
- First submitted after Tularik became part of Amgen
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Status unknown
- 4
- Terminated
- 2
- Suspended
- 1
Registry sponsor names on this page
- Tularik7 studies
Something wrong with this grouping? Tell us on the Amgen page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Amgen studies →
- Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerStatus unknownNCT00033722Phase 2
Sponsor listed in the registry: Tularik · First submitted before Tularik became part of Amgen
- T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous ChemotherapyStatus unknownNCT00022243Phase 2
Sponsor listed in the registry: Tularik · First submitted before Tularik became part of Amgen
- T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Phase 2/3
Sponsor listed in the registry: Tularik · First submitted before Tularik became part of Amgen
- Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.Status unknownNCT00043446Phase 2
Sponsor listed in the registry: Tularik · First submitted before Tularik became part of Amgen
- Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the EsophagusSuspendedNCT00048529Phase 2
Sponsor listed in the registry: Tularik · First submitted before Tularik became part of Amgen
- Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.TerminatedNCT00043459Phase 2
Sponsor listed in the registry: Tularik · First submitted before Tularik became part of Amgen
- Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.Status unknownNCT00043433Phase 2
Sponsor listed in the registry: Tularik · First submitted before Tularik became part of Amgen